Option Care Health Inc

Option Care Health reported second quarter 2026 net revenue of $1.44 billion, a 1.9% increase year over year, driven by high-single-digit organic growth in its acute therapy portfolio. Adjusted EBITDA rose 3% to $117.5 million, and adjusted EPS increased 9.8% to $0.45, including a $0.03 benefit from share repurchases. The company maintained its full-year revenue guidance of $5.675 billion to $5.775 billion but narrowed its adjusted EBITDA range to $480 million to $495 million and adjusted EPS to $1.85 to $1.92. Management cited stabilization in the chronic inflammatory disease patient census, sequential growth in IG neuro and rare and orphan portfolios, and the addition of five new ambulatory infusion clinics. Option Care Health repurchased $150 million of stock in the quarter, leaving $525 million under its current authorization, and ended with a net debt leverage ratio of 2.1 times.

Option Care Health reported second-quarter revenue of $1.44 billion, exceeding analyst estimates of $1.42 billion and marking a 1.9% year-on-year increase. Adjusted earnings per share came in at $0.45, a 5.4% beat over the consensus of $0.43, while adjusted EBITDA of $117.5 million also topped expectations. The company reconfirmed its full-year revenue guidance at $5.73 billion and slightly raised its adjusted EPS outlook to $1.89 at the midpoint. Management attributed the outperformance to high-single-digit organic growth in the acute therapy portfolio and stabilization in the chronic inflammatory disease segment, supported by cost controls and technology investments.

Companies across healthcare services, insurance, and cloud-managed services are deploying AI-driven automation to protect margins. Travelers disclosed that more than half of all claims are eligible for straight-through processing, with customers adopting it about two-thirds of the time, and framed efficiency gains as something that can fall to the bottom line through expense ratio flexibility. Concentrix reported its proprietary AI platform is running at an approximately $60 million run-rate on total spend of a little over $50 million, with expected margin improvement as it works through overcapacity and duplicate costs. Option Care Health is using AI to streamline patient onboarding workflows, aiming to scale patient census without proportional labor-force growth. DarioHealth expects its proprietary AI engine DarioIQ to increase recurring revenue from existing customers by 10 to 15 percent, with ROI tied to higher engagement and lifetime value without proportional acquisition cost growth.

Option Care Health has been ranked No. 15 on TIME's World's Most Impactful Companies 2026 list, highlighting its home and alternate-site infusion care model. The company describes itself as the nation's largest independent provider in that category, with more than 8,000 team members and over 5,000 clinicians serving patients in all 50 states. Analysts' average target implies roughly 30.5% upside for the stock. The recognition underscores the site-of-care substitution theme, where moving infusion services from hospitals to patient homes or alternate sites may offer lower costs while requiring clinical coordination, scale, and reliability.

A bullish thesis on Option Care Health, Inc. argues the stock offers an asymmetric risk-reward opportunity following a roughly 30 percent share price decline driven by Stelara biosimilar disruption. The company is the largest independent provider of home and alternate-site infusion services in the United States, with quarterly revenues in the $1.3 to $1.4 billion range and forward EBITDA margin guidance improving toward about 8.5 percent. The thesis contends that additional biosimilar or self-administration substitution risk is limited until late 2027 to 2028, and the valuation already reflects pessimism with a forward P/E near 11 times and EV/EBITDA around 10 times. Upside catalysts include insider buying, pipeline expansion into neurology, oncology, and rare disease infusibles, and secular tailwinds from the shift to home care, with a base case implying 10 to 35 percent upside and a bull case implying 35 to 50 percent upside over the next one to three quarters.